Showing results (21-30 of 443) with videos related to
Sort By:
Pageof 45
Lancet (London, England)|July 31, 2007
Chronic myeloid leukaemiaRüdiger Hehlmann, Andreas Hochhaus, Michele Baccarani, et al.Hematology/Oncology Clinics of North America|July 24, 2004
Monitoring of minimal residual disease in chronic myeloid leukemiaStefan Faderl, Andreas Hochhaus, Timothy HughesAnnals of Hematology|March 28, 2015
Response-related predictors of survival in CMLBenjamin Hanfstein, Martin C Müller, Andreas HochhausCancers|November 27, 2021
Management of Acute Myeloid Leukemia: Current Treatment Options and Future PerspectivesMaximilian Fleischmann, Ulf Schnetzke, Andreas Hochhaus, et al.Current Cancer Drug Targets|November 11, 2010
Current treatment concepts of CMLArmin A Leitner, Andreas Hochhaus, Martin C MüllerJournal of Cancer Research and Clinical Oncology|October 14, 2020
Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantationKristin Pulewka, Bernhard Strauss, Andreas Hochhaus, et al.Leukemia|September 19, 2023
Survival with chronic myeloid leukaemia after failing milestonesMichael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemiaJorge Cortes, Andreas Hochhaus, Timothy Hughes, et al.Molecular and Cellular Biochemistry|July 15, 2024
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signallingDarya Zibrova, Thomas Ernst, Andreas Hochhaus, et al.Seminars in Hematology|February 13, 2007
Resistance to targeted therapy in chronic myelogenous leukemiaAndreas Hochhaus, Philipp Erben, Thomas Ernst, et al.Pageof 45